Spinogenix Supports FRAXA Foundation in Pioneering Trial Against Fragile X Syndrome Spinogenix announces collaboration with FRAXA Research Foundation to advance Phase 2b trial of SPG601, aimed at treating Fragile X Syndrome.

Spinogenix Supports FRAXA Foundation in Pioneering Trial Against Fragile X Syndrome #USA #Los_Angeles #Spinogenix #Fragile_X_Syndrome #SPG601

Spinogenix Makes Significant Strides with Phase 2a Trial Results for Groundbreaking Fragile X Treatment at AACAP Spinogenix reveals full Phase 2a trial results for SPG601, a pioneering treatment for Fragile X Syndrome, showcasing promising cognitive improvements.

Spinogenix Makes Significant Strides with Phase 2a Trial Results for Groundbreaking Fragile X Treatment at AACAP #USA #Los_Angeles #Spinogenix #Fragile_X_Syndrome #SPG601

CONNECTA Therapeutics Secures EIC Funding for CTH120 Pediatric Development in Fragile X Syndrome CONNECTA Therapeutics has announced the launch of its pediatric development program for CTH120, a groundbreaking treatment for Fragile X Syndrome, supported by a €2.5M EIC grant.

CONNECTA Therapeutics Secures EIC Funding for CTH120 Pediatric Development in Fragile X Syndrome #Spain #Barcelona #Fragile_X_Syndrome #CONNECTA_Therapeutics #CTH120

Servier Expands Neurology Pipeline With Acquisition of KER-0193 for Fragile X Syndrome Servier's acquisition of KER-0193, a potential treatment for Fragile X syndrome, marks a pivotal step in expanding its neurology pipeline aimed at rare diseases.

Servier Expands Neurology Pipeline With Acquisition of KER-0193 for Fragile X Syndrome #France #Servier #Fragile_X_Syndrome #Suresnes #KER-0193

Servier Expands Neurology Pipeline with Acquisition of Potential Fragile X Syndrome Treatment Servier has recently acquired KER-0193, a promising treatment for Fragile X syndrome, enhancing its neurology pipeline with innovative therapies.

Servier Expands Neurology Pipeline with Acquisition of Potential Fragile X Syndrome Treatment #France #Servier #Fragile_X_Syndrome #Suresnes #KER-0193

Kaerus Bioscience's KER-0193 Achieves FDA Orphan Drug and Rare Pediatric Designations for Fragile X Syndrome Kaerus Bioscience's lead candidate KER-0193 receives Orphan Drug and Rare Pediatric Drug Designations from the FDA for treating Fragile X syndrome.

Kaerus Bioscience's KER-0193 Achieves FDA Orphan Drug and Rare Pediatric Designations for Fragile X Syndrome #United_States #London #Fragile_X_Syndrome #Kaerus_Bioscience #KER-0193

Spinogenix Advances to Phase 2 Study Completion for SPG601 Targeting Fragile X Syndrome Spinogenix announces promising results from its Phase 2 study of SPG601 for treating Fragile X syndrome, showing potential to improve quality of life.

Spinogenix Advances to Phase 2 Study Completion for SPG601 Targeting Fragile X Syndrome #USA #Los_Angeles #Spinogenix #Fragile_X_Syndrome #SPG601

FDA Fast Tracks Spinogenix's SPG601 for Fragile X Syndrome Treatment Amid Urgent Needs The FDA's Fast Track designation for Spinogenix's SPG601 marks significant progress in developing a treatment for Fragile X syndrome, a key cause of autism.

FDA Fast Tracks Spinogenix's SPG601 for Fragile X Syndrome Treatment Amid Urgent Needs #United_States #Los_Angeles #FDA #Spinogenix #Fragile_X_Syndrome